CGEN News Alert Compugen Ltd (CGEN) 7.98 12/16/2014 23:35:44

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Compugen Ltd (CGEN) 7.98 $CGEN

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), FPRX: 21.92 (+0.07), ZFGN: 21.67 (-0.08), CRIS: 1.15 (-0.01), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), ZGNX: 1.11 (-0.03), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), NDAQ: 45.74 (-0.72), FPRX: 21.92 (+0.07), CRIS: 1.15 (-0.01), ZFGN: 21.67 (-0.08), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Will Compugen (CGEN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:39AM CST
Will Compugen (CGEN) Continue to Surge Higher?
CGEN: 7.98 (-0.01)

Compugen (CGEN) Worth Watching: Stock Moves 8.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:25AM CST
Compugen (CGEN) was a big mover last session, with shares rising nearly 9% on the day.
BIIB: 325.13 (-10.67), ANIP: 55.08 (+1.32), CGEN: 7.98 (-0.01), AFFX: 8.90 (+0.10)

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 325.13 (-10.67), GILD: 100.46 (-2.70), CGEN: 7.98 (-0.01), ASPX: 25.09 (+0.78), GSK: 41.92 (+0.62), BMY: 57.69 (-0.86)

Compugen to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Dec 03, 6:01AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that Anat Cohen-Dayag, Ph.D., President and Chief Executive Office of Compugen, will present a company overview at the Oppenheimer 25th Annual Healthcare Conference in New York on Wednesday, December 10 at 2:10 p.m. ET.
CGEN: 7.98 (-0.01)

Shares of CGEN Down 14.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 02, 5:08PM CST
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on October 10th, 2014 at $7.85. In approximately 2 months, Compugen has returned 13.96% as of today's recent price of $6.75.
CGEN: 7.98 (-0.01)

Compugen Announces Experimental Confirmation of Additional Methodology for Discovery of Cancer-Related Immune Checkpoints
Business Wire - Tue Dec 02, 6:07AM CST
--Successful initial experimental results reported for drug target candidate identified through new methodology
CGEN: 7.98 (-0.01)

Investors' Radars Failed to Catch Compugen (CGEN), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 7:54AM CST
Compugen has seen a negative price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
CGEN: 7.98 (-0.01)

Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen
Brian Coleman - at Seeking Alpha - Fri Nov 21, 11:21AM CST

PFE: 30.67 (-0.19), MRK: 56.80 (-0.15), AZN: 69.56 (-0.18), CGEN: 7.98 (-0.01), GSK: 41.92 (+0.62), BMY: 57.69 (-0.86), NVS: 91.65 (+0.01)

Compugen (CGEN) Worth Watching: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:51AM CST
Compugen Ltd. (CGEN) was a big mover last session, as its shares rose nearly 6% on the day.
BIIB: 325.13 (-10.67), ANIP: 55.08 (+1.32), CGEN: 7.98 (-0.01), AMAG: 40.30 (+1.29)

17.1% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Wed Nov 19, 11:19AM CST
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on October 10th, 2014 at $7.85. In approximately 1 month, Compugen has returned 17.14% as of today's recent price of $6.50.
CGEN: 7.98 (-0.01)

Compugen (CGEN) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:45AM CST
Compugen (CGEN) Enters Oversold Territory
CGEN: 7.98 (-0.01)

Compugen Finance Wins Sustainability Award From Toronto Region Board of Trade
Marketwire Canada - Thu Nov 13, 10:20AM CST
Compugen Finance is proud to have won the Toronto Region Board of Trade's 2014 Business Excellence award for Sustainability. The Award was presented at the Business Excellence Awards Ceremony at Toronto Don Valley Hotel on 6 November 2014.
CGEN: 7.98 (-0.01)

Compugen to Present at Jefferies 2014 Global Healthcare Conference in London
Business Wire - Wed Nov 12, 6:02AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of Compugen, will present a corporate overview and update at the Jefferies 2014 Global Healthcare Conference in London, UK.
CGEN: 7.98 (-0.01)

Should Compugen (CGEN) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:35AM CST
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Compugen, the stock of which company has actually seen rising estimates over the past one month.
CGEN: 7.98 (-0.01)

Compugen incurs higher net loss of USD5.4m for Q3 2014
M2 - Thu Oct 30, 6:13AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) stated on Wednesday its net loss of USD5.4m (USD0.11 per diluted share) for the third quarter ending 30 September 2014.
CGEN: 7.98 (-0.01)

Compugen's (CGEN) CEO Anat Cohen-Dayag on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 2:07PM CDT

CGEN: 7.98 (-0.01)

Compugen ups revenues 6% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:04PM CDT

CGEN: 7.98 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 166

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 114

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 81

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Accredited Debt Relief Earns Personalized Honor in 2026

Updated Category News Views 185

A High Score Is Useful, Not a Free Pass Debt relief rankings can get awfully shiny when a company has a good week, but this one has some actual detail behind it. USA Today named Accredited Debt Relief its best provider for personalized debt relief in its 2026 review, handing the company a 94 out of 100. The ranking was published November 11 and updated November 12, and...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 236

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 36

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 176

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 88

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading

Top 5 Most Recently Viewed Articles

Fannie Mae Reports Strong Financial Update for Third Quarter

Updated Category News Views 81

Fannie Mae Reports Impressive Third Quarter Financial Results Fannie Mae has recently announced its financial performance for the third quarter of the year, marking a significant achievement with a net income of $4 billion. This statement underscores Fannie Mae's resilience and strategic efforts in the ongoing housing market. These results were disclosed alongside the...

Continue Reading
Willdan's Innovative Energy Design Assistance for Seattle

Updated Category News Views 51

Willdan Partners with Seattle for Energy Design Innovation Willdan Group, Inc. (NASDAQ: WLDN) is thrilled to announce that it has entered into a significant four-year contract to implement the Seattle City Light Energy Design Assistance Program. This initiative is a vital step toward enhancing sustainability in the development of multifamily and commercial buildings. With...

Continue Reading
Nikola Corporation Achieves Record Hydrogen Truck Deliveries

Updated Category News Views 79

Nikola Corporation Reports Impressive Third Quarter Results Nikola Corporation (NASDAQ: NKLA) has announced its third-quarter results, showcasing remarkable progress in its hydrogen fuel cell electric vehicle (FCEV) segment. The company registered a record 88 wholesale deliveries of hydrogen FCEVs, marking a 22% increase from the previous quarter. This significant growth...

Continue Reading
Tempest Therapeutics (TPST) Faces Major Stock Decline Today

Updated Category News Views 295

Understanding the Significant Decline of Tempest Therapeutics Stock Tempest Therapeutics Inc (NASDAQ: TPST) is experiencing a notable decrease in share value today. The sharp decline follows the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. Understanding the implications of this acquisition is crucial for investors and...

Continue Reading
FHU's Leadership Program Graduates First Cohort

Updated Category News Views 35

A New Dawn for School Leadership In the world of education, fresh thinking and dynamic leadership can often feel as profound as breakthroughs in any field. Today, we're celebrating a step in that direction. Freed-Hardeman University (FHU) in the heartland of Tennessee is marking a grand milestone. The university just rolled out its first cohort of graduates from the...

Continue Reading